GlassScriptPhysician profile
Melissa Stemen
NPI 1568023950
$2,632.40
in general payments reported to CMS, 2019-2025
20 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $694 · 2023: $529 · 2024: $491 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $379.71 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $286.25 | 2021-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $149.40 | 2022-2023 | Trelegy Ellipta |
| Bioventus LLC | $132.20 | 2025 | Exogen Ultrasound Bone Healing System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.20 | 2021 | |
| Therapeuticsmd, INC. | $100.00 | 2021 | |
| Pfizer INC. | $94.83 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $74.11 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.03 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.49 | 2021-2023 | Jardiance |
| Amgen INC. | $43.46 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $39.74 | 2021-2023 | Vaxneuvance, Varivax, Gardasil 9 |
| Corium, LLC | $30.46 | 2024-2025 | Azstarys |
| Lilly USA, LLC | $30.25 | 2023-2025 | Mounjaro, Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20.94 | 2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $17.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.20 | 2022 | |
| Axsome Therapeutics, INC. | $17.16 | 2023 | Auvelity |
| Abbott Laboratories | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Stemen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.